nodes	percent_of_prediction	percent_of_DWPC	metapath
Nedocromil—FPR1—renal system—prostate cancer	0.0202	0.129	CbGeAlD
Nedocromil—PTGDR—urethra—prostate cancer	0.0187	0.12	CbGeAlD
Nedocromil—FPR1—bone marrow—prostate cancer	0.0153	0.0977	CbGeAlD
Nedocromil—PTGDR—bone marrow—prostate cancer	0.0144	0.0923	CbGeAlD
Nedocromil—CYSLTR1—prostate gland—prostate cancer	0.0124	0.0793	CbGeAlD
Nedocromil—HSP90AA1—prostate gland—prostate cancer	0.0107	0.0688	CbGeAlD
Nedocromil—HSP90AA1—seminal vesicle—prostate cancer	0.00909	0.0582	CbGeAlD
Nedocromil—PTGDR—lymph node—prostate cancer	0.00893	0.0572	CbGeAlD
Nedocromil—HSP90AA1—epithelium—prostate cancer	0.0079	0.0505	CbGeAlD
Nedocromil—HSP90AA1—renal system—prostate cancer	0.00732	0.0469	CbGeAlD
Nedocromil—HSP90AA1—urethra—prostate cancer	0.00719	0.0461	CbGeAlD
Nedocromil—CYSLTR1—bone marrow—prostate cancer	0.00638	0.0409	CbGeAlD
Nedocromil—HSP90AA1—bone marrow—prostate cancer	0.00554	0.0354	CbGeAlD
Nedocromil—HSP90AA1—testis—prostate cancer	0.00473	0.0303	CbGeAlD
Nedocromil—CYSLTR1—lymph node—prostate cancer	0.00395	0.0253	CbGeAlD
Nedocromil—HSP90AA1—lymph node—prostate cancer	0.00343	0.022	CbGeAlD
Nedocromil—Asthenia—Ethinyl Estradiol—prostate cancer	0.000555	0.00156	CcSEcCtD
Nedocromil—Influenza—Capecitabine—prostate cancer	0.000554	0.00155	CcSEcCtD
Nedocromil—Fatigue—Goserelin—prostate cancer	0.000549	0.00154	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.000545	0.00153	CcSEcCtD
Nedocromil—Pain—Goserelin—prostate cancer	0.000545	0.00153	CcSEcCtD
Nedocromil—Fatigue—Conjugated Estrogens—prostate cancer	0.000544	0.00152	CcSEcCtD
Nedocromil—Nausea—Bicalutamide—prostate cancer	0.000544	0.00152	CcSEcCtD
Nedocromil—Cough—Estradiol—prostate cancer	0.00054	0.00151	CcSEcCtD
Nedocromil—Pain—Conjugated Estrogens—prostate cancer	0.00054	0.00151	CcSEcCtD
Nedocromil—Bronchitis—Capecitabine—prostate cancer	0.000533	0.00149	CcSEcCtD
Nedocromil—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.00053	0.00148	CcSEcCtD
Nedocromil—Chest pain—Estradiol—prostate cancer	0.000527	0.00148	CcSEcCtD
Nedocromil—Gastrointestinal pain—Goserelin—prostate cancer	0.000521	0.00146	CcSEcCtD
Nedocromil—Leukopenia—Mitoxantrone—prostate cancer	0.000516	0.00145	CcSEcCtD
Nedocromil—Gastrointestinal pain—Conjugated Estrogens—prostate cancer	0.000516	0.00145	CcSEcCtD
Nedocromil—Dry mouth—Estradiol—prostate cancer	0.000515	0.00144	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Capecitabine—prostate cancer	0.000515	0.00144	CcSEcCtD
Nedocromil—Pneumonia—Docetaxel—prostate cancer	0.000513	0.00144	CcSEcCtD
Nedocromil—Dizziness—Ethinyl Estradiol—prostate cancer	0.000512	0.00143	CcSEcCtD
Nedocromil—Urticaria—Goserelin—prostate cancer	0.000506	0.00142	CcSEcCtD
Nedocromil—Anaphylactic shock—Estradiol—prostate cancer	0.000505	0.00142	CcSEcCtD
Nedocromil—Abdominal pain—Goserelin—prostate cancer	0.000504	0.00141	CcSEcCtD
Nedocromil—Body temperature increased—Goserelin—prostate cancer	0.000504	0.00141	CcSEcCtD
Nedocromil—Cough—Mitoxantrone—prostate cancer	0.000503	0.00141	CcSEcCtD
Nedocromil—Urticaria—Conjugated Estrogens—prostate cancer	0.000501	0.0014	CcSEcCtD
Nedocromil—Body temperature increased—Conjugated Estrogens—prostate cancer	0.000499	0.0014	CcSEcCtD
Nedocromil—Abdominal pain—Conjugated Estrogens—prostate cancer	0.000499	0.0014	CcSEcCtD
Nedocromil—Eczema—Epirubicin—prostate cancer	0.000497	0.00139	CcSEcCtD
Nedocromil—Pneumonia—Capecitabine—prostate cancer	0.000497	0.00139	CcSEcCtD
Nedocromil—Conjunctivitis—Docetaxel—prostate cancer	0.000496	0.00139	CcSEcCtD
Nedocromil—Vomiting—Ethinyl Estradiol—prostate cancer	0.000492	0.00138	CcSEcCtD
Nedocromil—Chest pain—Mitoxantrone—prostate cancer	0.000491	0.00138	CcSEcCtD
Nedocromil—Rash—Ethinyl Estradiol—prostate cancer	0.000488	0.00137	CcSEcCtD
Nedocromil—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000488	0.00137	CcSEcCtD
Nedocromil—Headache—Ethinyl Estradiol—prostate cancer	0.000485	0.00136	CcSEcCtD
Nedocromil—Conjunctivitis—Capecitabine—prostate cancer	0.00048	0.00135	CcSEcCtD
Nedocromil—Anaphylactic shock—Mitoxantrone—prostate cancer	0.000471	0.00132	CcSEcCtD
Nedocromil—Dysgeusia—Etoposide—prostate cancer	0.00047	0.00132	CcSEcCtD
Nedocromil—Hypersensitivity—Goserelin—prostate cancer	0.000469	0.00132	CcSEcCtD
Nedocromil—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000465	0.0013	CcSEcCtD
Nedocromil—Nausea—Ethinyl Estradiol—prostate cancer	0.00046	0.00129	CcSEcCtD
Nedocromil—Eczema—Doxorubicin—prostate cancer	0.00046	0.00129	CcSEcCtD
Nedocromil—Rhinitis—Docetaxel—prostate cancer	0.000459	0.00129	CcSEcCtD
Nedocromil—Asthenia—Goserelin—prostate cancer	0.000457	0.00128	CcSEcCtD
Nedocromil—Pharyngitis—Docetaxel—prostate cancer	0.000455	0.00127	CcSEcCtD
Nedocromil—Asthenia—Conjugated Estrogens—prostate cancer	0.000453	0.00127	CcSEcCtD
Nedocromil—Dyspnoea—Estradiol—prostate cancer	0.00045	0.00126	CcSEcCtD
Nedocromil—Dyspepsia—Estradiol—prostate cancer	0.000445	0.00125	CcSEcCtD
Nedocromil—Rhinitis—Capecitabine—prostate cancer	0.000444	0.00125	CcSEcCtD
Nedocromil—Visual impairment—Docetaxel—prostate cancer	0.000441	0.00124	CcSEcCtD
Nedocromil—Pharyngitis—Capecitabine—prostate cancer	0.00044	0.00123	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Estradiol—prostate cancer	0.000436	0.00122	CcSEcCtD
Nedocromil—Diarrhoea—Goserelin—prostate cancer	0.000436	0.00122	CcSEcCtD
Nedocromil—Fatigue—Estradiol—prostate cancer	0.000435	0.00122	CcSEcCtD
Nedocromil—Pain—Estradiol—prostate cancer	0.000432	0.00121	CcSEcCtD
Nedocromil—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000432	0.00121	CcSEcCtD
Nedocromil—Leukopenia—Etoposide—prostate cancer	0.000429	0.0012	CcSEcCtD
Nedocromil—Visual impairment—Capecitabine—prostate cancer	0.000427	0.0012	CcSEcCtD
Nedocromil—Dizziness—Goserelin—prostate cancer	0.000421	0.00118	CcSEcCtD
Nedocromil—Dyspnoea—Mitoxantrone—prostate cancer	0.00042	0.00118	CcSEcCtD
Nedocromil—Cough—Etoposide—prostate cancer	0.000419	0.00117	CcSEcCtD
Nedocromil—Dizziness—Conjugated Estrogens—prostate cancer	0.000417	0.00117	CcSEcCtD
Nedocromil—Dyspepsia—Mitoxantrone—prostate cancer	0.000414	0.00116	CcSEcCtD
Nedocromil—Gastrointestinal pain—Estradiol—prostate cancer	0.000413	0.00116	CcSEcCtD
Nedocromil—Chest pain—Etoposide—prostate cancer	0.000408	0.00114	CcSEcCtD
Nedocromil—Fatigue—Mitoxantrone—prostate cancer	0.000406	0.00114	CcSEcCtD
Nedocromil—Vomiting—Goserelin—prostate cancer	0.000405	0.00114	CcSEcCtD
Nedocromil—Pain—Mitoxantrone—prostate cancer	0.000402	0.00113	CcSEcCtD
Nedocromil—Rash—Goserelin—prostate cancer	0.000402	0.00113	CcSEcCtD
Nedocromil—Dermatitis—Goserelin—prostate cancer	0.000401	0.00112	CcSEcCtD
Nedocromil—Vomiting—Conjugated Estrogens—prostate cancer	0.000401	0.00112	CcSEcCtD
Nedocromil—Urticaria—Estradiol—prostate cancer	0.000401	0.00112	CcSEcCtD
Nedocromil—Abdominal pain—Estradiol—prostate cancer	0.000399	0.00112	CcSEcCtD
Nedocromil—Body temperature increased—Estradiol—prostate cancer	0.000399	0.00112	CcSEcCtD
Nedocromil—Headache—Goserelin—prostate cancer	0.000399	0.00112	CcSEcCtD
Nedocromil—Rash—Conjugated Estrogens—prostate cancer	0.000398	0.00112	CcSEcCtD
Nedocromil—Dermatitis—Conjugated Estrogens—prostate cancer	0.000398	0.00111	CcSEcCtD
Nedocromil—Headache—Conjugated Estrogens—prostate cancer	0.000395	0.00111	CcSEcCtD
Nedocromil—Anaphylactic shock—Etoposide—prostate cancer	0.000391	0.0011	CcSEcCtD
Nedocromil—Dysgeusia—Docetaxel—prostate cancer	0.00039	0.00109	CcSEcCtD
Nedocromil—Influenza—Epirubicin—prostate cancer	0.000386	0.00108	CcSEcCtD
Nedocromil—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000385	0.00108	CcSEcCtD
Nedocromil—Eosinophilia—Epirubicin—prostate cancer	0.000382	0.00107	CcSEcCtD
Nedocromil—Nausea—Goserelin—prostate cancer	0.000378	0.00106	CcSEcCtD
Nedocromil—Dysgeusia—Capecitabine—prostate cancer	0.000378	0.00106	CcSEcCtD
Nedocromil—Nausea—Conjugated Estrogens—prostate cancer	0.000375	0.00105	CcSEcCtD
Nedocromil—Urticaria—Mitoxantrone—prostate cancer	0.000374	0.00105	CcSEcCtD
Nedocromil—Hypersensitivity—Estradiol—prostate cancer	0.000372	0.00104	CcSEcCtD
Nedocromil—Body temperature increased—Mitoxantrone—prostate cancer	0.000372	0.00104	CcSEcCtD
Nedocromil—Abdominal pain—Mitoxantrone—prostate cancer	0.000372	0.00104	CcSEcCtD
Nedocromil—Bronchitis—Epirubicin—prostate cancer	0.000371	0.00104	CcSEcCtD
Nedocromil—Asthenia—Estradiol—prostate cancer	0.000362	0.00102	CcSEcCtD
Nedocromil—Tremor—Capecitabine—prostate cancer	0.000362	0.00101	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Epirubicin—prostate cancer	0.000359	0.00101	CcSEcCtD
Nedocromil—Influenza—Doxorubicin—prostate cancer	0.000357	0.001	CcSEcCtD
Nedocromil—Leukopenia—Docetaxel—prostate cancer	0.000357	0.001	CcSEcCtD
Nedocromil—Eosinophilia—Doxorubicin—prostate cancer	0.000354	0.000991	CcSEcCtD
Nedocromil—Dyspnoea—Etoposide—prostate cancer	0.000349	0.000978	CcSEcCtD
Nedocromil—Cough—Docetaxel—prostate cancer	0.000348	0.000975	CcSEcCtD
Nedocromil—Hypersensitivity—Mitoxantrone—prostate cancer	0.000347	0.000972	CcSEcCtD
Nedocromil—Pneumonia—Epirubicin—prostate cancer	0.000346	0.00097	CcSEcCtD
Nedocromil—Diarrhoea—Estradiol—prostate cancer	0.000346	0.000968	CcSEcCtD
Nedocromil—Leukopenia—Capecitabine—prostate cancer	0.000345	0.000968	CcSEcCtD
Nedocromil—Bronchitis—Doxorubicin—prostate cancer	0.000343	0.000962	CcSEcCtD
Nedocromil—Chest pain—Docetaxel—prostate cancer	0.000339	0.000951	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Etoposide—prostate cancer	0.000338	0.000947	CcSEcCtD
Nedocromil—Asthenia—Mitoxantrone—prostate cancer	0.000338	0.000946	CcSEcCtD
Nedocromil—Fatigue—Etoposide—prostate cancer	0.000338	0.000946	CcSEcCtD
Nedocromil—Cough—Capecitabine—prostate cancer	0.000337	0.000944	CcSEcCtD
Nedocromil—Pain—Etoposide—prostate cancer	0.000335	0.000938	CcSEcCtD
Nedocromil—Conjunctivitis—Epirubicin—prostate cancer	0.000334	0.000937	CcSEcCtD
Nedocromil—Dizziness—Estradiol—prostate cancer	0.000334	0.000936	CcSEcCtD
Nedocromil—Dry mouth—Docetaxel—prostate cancer	0.000332	0.00093	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Doxorubicin—prostate cancer	0.000332	0.00093	CcSEcCtD
Nedocromil—Chest pain—Capecitabine—prostate cancer	0.000329	0.000921	CcSEcCtD
Nedocromil—Anaphylactic shock—Docetaxel—prostate cancer	0.000325	0.000912	CcSEcCtD
Nedocromil—Sinusitis—Epirubicin—prostate cancer	0.000323	0.000905	CcSEcCtD
Nedocromil—Diarrhoea—Mitoxantrone—prostate cancer	0.000322	0.000902	CcSEcCtD
Nedocromil—Dry mouth—Capecitabine—prostate cancer	0.000321	0.000901	CcSEcCtD
Nedocromil—Vomiting—Estradiol—prostate cancer	0.000321	0.0009	CcSEcCtD
Nedocromil—Pneumonia—Doxorubicin—prostate cancer	0.00032	0.000897	CcSEcCtD
Nedocromil—Gastrointestinal pain—Etoposide—prostate cancer	0.00032	0.000897	CcSEcCtD
Nedocromil—Rash—Estradiol—prostate cancer	0.000318	0.000892	CcSEcCtD
Nedocromil—Dermatitis—Estradiol—prostate cancer	0.000318	0.000892	CcSEcCtD
Nedocromil—Headache—Estradiol—prostate cancer	0.000316	0.000887	CcSEcCtD
Nedocromil—Urticaria—Etoposide—prostate cancer	0.000311	0.000871	CcSEcCtD
Nedocromil—Rhinitis—Epirubicin—prostate cancer	0.00031	0.000868	CcSEcCtD
Nedocromil—Body temperature increased—Etoposide—prostate cancer	0.000309	0.000867	CcSEcCtD
Nedocromil—Abdominal pain—Etoposide—prostate cancer	0.000309	0.000867	CcSEcCtD
Nedocromil—Conjunctivitis—Doxorubicin—prostate cancer	0.000309	0.000867	CcSEcCtD
Nedocromil—Pharyngitis—Epirubicin—prostate cancer	0.000307	0.000859	CcSEcCtD
Nedocromil—Nausea—Estradiol—prostate cancer	0.0003	0.000841	CcSEcCtD
Nedocromil—Vomiting—Mitoxantrone—prostate cancer	0.000299	0.000839	CcSEcCtD
Nedocromil—Sinusitis—Doxorubicin—prostate cancer	0.000299	0.000837	CcSEcCtD
Nedocromil—Visual impairment—Epirubicin—prostate cancer	0.000298	0.000834	CcSEcCtD
Nedocromil—Rash—Mitoxantrone—prostate cancer	0.000297	0.000832	CcSEcCtD
Nedocromil—Dermatitis—Mitoxantrone—prostate cancer	0.000296	0.000831	CcSEcCtD
Nedocromil—Headache—Mitoxantrone—prostate cancer	0.000295	0.000826	CcSEcCtD
Nedocromil—Dyspnoea—Docetaxel—prostate cancer	0.00029	0.000813	CcSEcCtD
Nedocromil—Hypersensitivity—Etoposide—prostate cancer	0.000288	0.000808	CcSEcCtD
Nedocromil—Rhinitis—Doxorubicin—prostate cancer	0.000287	0.000803	CcSEcCtD
Nedocromil—Dyspepsia—Docetaxel—prostate cancer	0.000286	0.000803	CcSEcCtD
Nedocromil—Pharyngitis—Doxorubicin—prostate cancer	0.000284	0.000795	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000281	0.000787	CcSEcCtD
Nedocromil—Asthenia—Etoposide—prostate cancer	0.000281	0.000787	CcSEcCtD
Nedocromil—Dyspnoea—Capecitabine—prostate cancer	0.000281	0.000787	CcSEcCtD
Nedocromil—Anaphylactic shock—Prednisone—prostate cancer	0.000281	0.000786	CcSEcCtD
Nedocromil—Fatigue—Docetaxel—prostate cancer	0.00028	0.000786	CcSEcCtD
Nedocromil—Nausea—Mitoxantrone—prostate cancer	0.00028	0.000783	CcSEcCtD
Nedocromil—Pain—Docetaxel—prostate cancer	0.000278	0.00078	CcSEcCtD
Nedocromil—Dyspepsia—Capecitabine—prostate cancer	0.000277	0.000777	CcSEcCtD
Nedocromil—Visual impairment—Doxorubicin—prostate cancer	0.000275	0.000772	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000272	0.000762	CcSEcCtD
Nedocromil—Fatigue—Capecitabine—prostate cancer	0.000272	0.000761	CcSEcCtD
Nedocromil—Pain—Capecitabine—prostate cancer	0.000269	0.000755	CcSEcCtD
Nedocromil—Diarrhoea—Etoposide—prostate cancer	0.000268	0.000751	CcSEcCtD
Nedocromil—Gastrointestinal pain—Docetaxel—prostate cancer	0.000266	0.000746	CcSEcCtD
Nedocromil—Dysgeusia—Epirubicin—prostate cancer	0.000263	0.000738	CcSEcCtD
Nedocromil—Dizziness—Etoposide—prostate cancer	0.000259	0.000725	CcSEcCtD
Nedocromil—Gastrointestinal pain—Capecitabine—prostate cancer	0.000258	0.000722	CcSEcCtD
Nedocromil—Abdominal pain—Docetaxel—prostate cancer	0.000257	0.000721	CcSEcCtD
Nedocromil—Body temperature increased—Docetaxel—prostate cancer	0.000257	0.000721	CcSEcCtD
Nedocromil—Urticaria—Capecitabine—prostate cancer	0.00025	0.000701	CcSEcCtD
Nedocromil—Body temperature increased—Capecitabine—prostate cancer	0.000249	0.000698	CcSEcCtD
Nedocromil—Abdominal pain—Capecitabine—prostate cancer	0.000249	0.000698	CcSEcCtD
Nedocromil—Vomiting—Etoposide—prostate cancer	0.000249	0.000698	CcSEcCtD
Nedocromil—Dyspepsia—Prednisone—prostate cancer	0.000247	0.000692	CcSEcCtD
Nedocromil—Rash—Etoposide—prostate cancer	0.000247	0.000692	CcSEcCtD
Nedocromil—Dermatitis—Etoposide—prostate cancer	0.000247	0.000691	CcSEcCtD
Nedocromil—Headache—Etoposide—prostate cancer	0.000245	0.000687	CcSEcCtD
Nedocromil—Dysgeusia—Doxorubicin—prostate cancer	0.000244	0.000683	CcSEcCtD
Nedocromil—Fatigue—Prednisone—prostate cancer	0.000242	0.000678	CcSEcCtD
Nedocromil—Leukopenia—Epirubicin—prostate cancer	0.000241	0.000674	CcSEcCtD
Nedocromil—Hypersensitivity—Docetaxel—prostate cancer	0.00024	0.000672	CcSEcCtD
Nedocromil—Cough—Epirubicin—prostate cancer	0.000235	0.000657	CcSEcCtD
Nedocromil—Asthenia—Docetaxel—prostate cancer	0.000233	0.000654	CcSEcCtD
Nedocromil—Nausea—Etoposide—prostate cancer	0.000233	0.000652	CcSEcCtD
Nedocromil—Hypersensitivity—Capecitabine—prostate cancer	0.000232	0.00065	CcSEcCtD
Nedocromil—Gastrointestinal pain—Prednisone—prostate cancer	0.000229	0.000643	CcSEcCtD
Nedocromil—Chest pain—Epirubicin—prostate cancer	0.000229	0.000641	CcSEcCtD
Nedocromil—Asthenia—Capecitabine—prostate cancer	0.000226	0.000633	CcSEcCtD
Nedocromil—Dry mouth—Epirubicin—prostate cancer	0.000224	0.000627	CcSEcCtD
Nedocromil—Urticaria—Prednisone—prostate cancer	0.000223	0.000625	CcSEcCtD
Nedocromil—Leukopenia—Doxorubicin—prostate cancer	0.000223	0.000624	CcSEcCtD
Nedocromil—Diarrhoea—Docetaxel—prostate cancer	0.000223	0.000624	CcSEcCtD
Nedocromil—Abdominal pain—Prednisone—prostate cancer	0.000222	0.000622	CcSEcCtD
Nedocromil—Body temperature increased—Prednisone—prostate cancer	0.000222	0.000622	CcSEcCtD
Nedocromil—Anaphylactic shock—Epirubicin—prostate cancer	0.000219	0.000615	CcSEcCtD
Nedocromil—Cough—Doxorubicin—prostate cancer	0.000217	0.000608	CcSEcCtD
Nedocromil—Diarrhoea—Capecitabine—prostate cancer	0.000216	0.000604	CcSEcCtD
Nedocromil—Dizziness—Docetaxel—prostate cancer	0.000215	0.000603	CcSEcCtD
Nedocromil—Chest pain—Doxorubicin—prostate cancer	0.000212	0.000594	CcSEcCtD
Nedocromil—Dizziness—Capecitabine—prostate cancer	0.000208	0.000584	CcSEcCtD
Nedocromil—Dry mouth—Doxorubicin—prostate cancer	0.000207	0.00058	CcSEcCtD
Nedocromil—Vomiting—Docetaxel—prostate cancer	0.000207	0.00058	CcSEcCtD
Nedocromil—Hypersensitivity—Prednisone—prostate cancer	0.000207	0.000579	CcSEcCtD
Nedocromil—Rash—Docetaxel—prostate cancer	0.000205	0.000575	CcSEcCtD
Nedocromil—Dermatitis—Docetaxel—prostate cancer	0.000205	0.000574	CcSEcCtD
Nedocromil—Headache—Docetaxel—prostate cancer	0.000204	0.000571	CcSEcCtD
Nedocromil—Anaphylactic shock—Doxorubicin—prostate cancer	0.000203	0.000569	CcSEcCtD
Nedocromil—Asthenia—Prednisone—prostate cancer	0.000201	0.000564	CcSEcCtD
Nedocromil—Vomiting—Capecitabine—prostate cancer	0.0002	0.000561	CcSEcCtD
Nedocromil—Rash—Capecitabine—prostate cancer	0.000199	0.000557	CcSEcCtD
Nedocromil—Dermatitis—Capecitabine—prostate cancer	0.000198	0.000556	CcSEcCtD
Nedocromil—Headache—Capecitabine—prostate cancer	0.000197	0.000553	CcSEcCtD
Nedocromil—Dyspnoea—Epirubicin—prostate cancer	0.000196	0.000548	CcSEcCtD
Nedocromil—Nausea—Docetaxel—prostate cancer	0.000193	0.000542	CcSEcCtD
Nedocromil—Dyspepsia—Epirubicin—prostate cancer	0.000193	0.000541	CcSEcCtD
Nedocromil—Diarrhoea—Prednisone—prostate cancer	0.000192	0.000538	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000189	0.000531	CcSEcCtD
Nedocromil—Fatigue—Epirubicin—prostate cancer	0.000189	0.00053	CcSEcCtD
Nedocromil—Pain—Epirubicin—prostate cancer	0.000188	0.000526	CcSEcCtD
Nedocromil—Nausea—Capecitabine—prostate cancer	0.000187	0.000524	CcSEcCtD
Nedocromil—Dizziness—Prednisone—prostate cancer	0.000186	0.00052	CcSEcCtD
Nedocromil—Dyspnoea—Doxorubicin—prostate cancer	0.000181	0.000507	CcSEcCtD
Nedocromil—Gastrointestinal pain—Epirubicin—prostate cancer	0.000179	0.000503	CcSEcCtD
Nedocromil—Dyspepsia—Doxorubicin—prostate cancer	0.000179	0.000501	CcSEcCtD
Nedocromil—Vomiting—Prednisone—prostate cancer	0.000178	0.0005	CcSEcCtD
Nedocromil—Rash—Prednisone—prostate cancer	0.000177	0.000496	CcSEcCtD
Nedocromil—Dermatitis—Prednisone—prostate cancer	0.000177	0.000495	CcSEcCtD
Nedocromil—Headache—Prednisone—prostate cancer	0.000176	0.000493	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000175	0.000491	CcSEcCtD
Nedocromil—Fatigue—Doxorubicin—prostate cancer	0.000175	0.000491	CcSEcCtD
Nedocromil—Urticaria—Epirubicin—prostate cancer	0.000174	0.000489	CcSEcCtD
Nedocromil—Pain—Doxorubicin—prostate cancer	0.000174	0.000487	CcSEcCtD
Nedocromil—Abdominal pain—Epirubicin—prostate cancer	0.000173	0.000486	CcSEcCtD
Nedocromil—Body temperature increased—Epirubicin—prostate cancer	0.000173	0.000486	CcSEcCtD
Nedocromil—Nausea—Prednisone—prostate cancer	0.000167	0.000467	CcSEcCtD
Nedocromil—Gastrointestinal pain—Doxorubicin—prostate cancer	0.000166	0.000465	CcSEcCtD
Nedocromil—Hypersensitivity—Epirubicin—prostate cancer	0.000162	0.000453	CcSEcCtD
Nedocromil—Urticaria—Doxorubicin—prostate cancer	0.000161	0.000452	CcSEcCtD
Nedocromil—Body temperature increased—Doxorubicin—prostate cancer	0.000161	0.00045	CcSEcCtD
Nedocromil—Abdominal pain—Doxorubicin—prostate cancer	0.000161	0.00045	CcSEcCtD
Nedocromil—Asthenia—Epirubicin—prostate cancer	0.000157	0.000441	CcSEcCtD
Nedocromil—Diarrhoea—Epirubicin—prostate cancer	0.00015	0.000421	CcSEcCtD
Nedocromil—Hypersensitivity—Doxorubicin—prostate cancer	0.00015	0.000419	CcSEcCtD
Nedocromil—Asthenia—Doxorubicin—prostate cancer	0.000146	0.000408	CcSEcCtD
Nedocromil—Dizziness—Epirubicin—prostate cancer	0.000145	0.000407	CcSEcCtD
Nedocromil—Vomiting—Epirubicin—prostate cancer	0.00014	0.000391	CcSEcCtD
Nedocromil—Diarrhoea—Doxorubicin—prostate cancer	0.000139	0.000389	CcSEcCtD
Nedocromil—Rash—Epirubicin—prostate cancer	0.000138	0.000388	CcSEcCtD
Nedocromil—Dermatitis—Epirubicin—prostate cancer	0.000138	0.000387	CcSEcCtD
Nedocromil—Headache—Epirubicin—prostate cancer	0.000137	0.000385	CcSEcCtD
Nedocromil—Dizziness—Doxorubicin—prostate cancer	0.000134	0.000376	CcSEcCtD
Nedocromil—Nausea—Epirubicin—prostate cancer	0.00013	0.000365	CcSEcCtD
Nedocromil—Vomiting—Doxorubicin—prostate cancer	0.000129	0.000362	CcSEcCtD
Nedocromil—Rash—Doxorubicin—prostate cancer	0.000128	0.000359	CcSEcCtD
Nedocromil—Dermatitis—Doxorubicin—prostate cancer	0.000128	0.000358	CcSEcCtD
Nedocromil—Headache—Doxorubicin—prostate cancer	0.000127	0.000356	CcSEcCtD
Nedocromil—Nausea—Doxorubicin—prostate cancer	0.000121	0.000338	CcSEcCtD
Nedocromil—HSP90AA1—Signaling Pathways—NGFR—prostate cancer	2.97e-05	6.1e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PRKCQ—prostate cancer	2.97e-05	6.1e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—HIF1A—prostate cancer	2.97e-05	6.1e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—EGFR—prostate cancer	2.96e-05	6.09e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—EP300—prostate cancer	2.96e-05	6.08e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—GSTM1—prostate cancer	2.95e-05	6.06e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—ICAM1—prostate cancer	2.95e-05	6.05e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MAP3K7—prostate cancer	2.93e-05	6.03e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—BAD—prostate cancer	2.93e-05	6.01e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—PIK3CA—prostate cancer	2.91e-05	5.98e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—VEGFA—prostate cancer	2.91e-05	5.97e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MDM2—prostate cancer	2.9e-05	5.95e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—HIF1A—prostate cancer	2.9e-05	5.95e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—LPL—prostate cancer	2.9e-05	5.95e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—SRC—prostate cancer	2.88e-05	5.92e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—STAT3—prostate cancer	2.88e-05	5.91e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CAV1—prostate cancer	2.87e-05	5.9e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—ERBB2—prostate cancer	2.86e-05	5.87e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—LEP—prostate cancer	2.83e-05	5.81e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—FGF10—prostate cancer	2.82e-05	5.8e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PIK3CB—prostate cancer	2.82e-05	5.79e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—VEGFA—prostate cancer	2.81e-05	5.76e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—MYC—prostate cancer	2.81e-05	5.76e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CAV1—prostate cancer	2.8e-05	5.75e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—EGF—prostate cancer	2.8e-05	5.75e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IRS1—prostate cancer	2.8e-05	5.75e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—KRAS—prostate cancer	2.8e-05	5.75e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CYP1A1—prostate cancer	2.8e-05	5.74e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ADRB2—prostate cancer	2.79e-05	5.73e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—STAT3—prostate cancer	2.78e-05	5.71e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—ERCC2—prostate cancer	2.77e-05	5.7e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—KDR—prostate cancer	2.77e-05	5.69e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—VAV3—prostate cancer	2.72e-05	5.59e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—GSK3B—prostate cancer	2.72e-05	5.58e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CXCL8—prostate cancer	2.71e-05	5.57e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—BAD—prostate cancer	2.7e-05	5.55e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—ESR1—prostate cancer	2.7e-05	5.54e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TGFBR2—prostate cancer	2.68e-05	5.51e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—MYC—prostate cancer	2.67e-05	5.49e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—TGFB1—prostate cancer	2.67e-05	5.48e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CDKN1B—prostate cancer	2.65e-05	5.44e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ITPR1—prostate cancer	2.64e-05	5.42e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—BAD—prostate cancer	2.63e-05	5.41e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CREBBP—prostate cancer	2.63e-05	5.39e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—AKT1—prostate cancer	2.62e-05	5.38e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—EGFR—prostate cancer	2.62e-05	5.38e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—APC—prostate cancer	2.62e-05	5.37e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—EGFR—prostate cancer	2.61e-05	5.37e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CDH1—prostate cancer	2.61e-05	5.35e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—MTHFR—prostate cancer	2.61e-05	5.35e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CASP3—prostate cancer	2.59e-05	5.33e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IL2—prostate cancer	2.59e-05	5.32e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—EGF—prostate cancer	2.59e-05	5.31e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—IRS1—prostate cancer	2.59e-05	5.31e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—MYC—prostate cancer	2.58e-05	5.3e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—IL6—prostate cancer	2.58e-05	5.29e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TGFB1—prostate cancer	2.58e-05	5.29e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PPARA—prostate cancer	2.56e-05	5.25e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—APC—prostate cancer	2.55e-05	5.24e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CG—prostate cancer	2.55e-05	5.24e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CCND1—prostate cancer	2.53e-05	5.19e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IGF1R—prostate cancer	2.53e-05	5.19e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—EGFR—prostate cancer	2.52e-05	5.19e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—EGF—prostate cancer	2.52e-05	5.18e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IRS1—prostate cancer	2.52e-05	5.18e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—GSK3B—prostate cancer	2.51e-05	5.15e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MAP2K1—prostate cancer	2.51e-05	5.15e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CTNNB1—prostate cancer	2.5e-05	5.14e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CD—prostate cancer	2.49e-05	5.11e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—INS—prostate cancer	2.48e-05	5.08e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—KRAS—prostate cancer	2.47e-05	5.08e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—KRAS—prostate cancer	2.47e-05	5.07e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MMP9—prostate cancer	2.45e-05	5.04e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—GSK3B—prostate cancer	2.45e-05	5.03e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CDKN1A—prostate cancer	2.44e-05	5.02e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PTEN—prostate cancer	2.44e-05	5.01e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CREBBP—prostate cancer	2.42e-05	4.98e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—LPL—prostate cancer	2.42e-05	4.97e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—INS—prostate cancer	2.42e-05	4.96e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CAV1—prostate cancer	2.4e-05	4.94e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PDGFRB—prostate cancer	2.4e-05	4.93e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—KRAS—prostate cancer	2.39e-05	4.9e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—FGF2—prostate cancer	2.38e-05	4.9e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—AKT1—prostate cancer	2.38e-05	4.88e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CREBBP—prostate cancer	2.37e-05	4.86e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ITGB3—prostate cancer	2.34e-05	4.8e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IGF1—prostate cancer	2.34e-05	4.8e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—EGFR—prostate cancer	2.32e-05	4.77e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—EP300—prostate cancer	2.32e-05	4.77e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MAP2K1—prostate cancer	2.31e-05	4.75e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—TP53—prostate cancer	2.3e-05	4.73e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CD—prostate cancer	2.3e-05	4.72e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—JAK2—prostate cancer	2.29e-05	4.69e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—IL6—prostate cancer	2.28e-05	4.68e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—SERPINE1—prostate cancer	2.27e-05	4.67e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—PIK3CA—prostate cancer	2.27e-05	4.67e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—PIK3CA—prostate cancer	2.27e-05	4.66e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ERBB3—prostate cancer	2.27e-05	4.66e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—FGFR2—prostate cancer	2.26e-05	4.65e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—BCL2—prostate cancer	2.26e-05	4.65e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—SRC—prostate cancer	2.26e-05	4.64e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MAP2K1—prostate cancer	2.26e-05	4.64e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CD—prostate cancer	2.24e-05	4.61e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MDM2—prostate cancer	2.23e-05	4.58e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—PIK3CA—prostate cancer	2.22e-05	4.56e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—SERPINE1—prostate cancer	2.22e-05	4.56e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—VEGFA—prostate cancer	2.2e-05	4.52e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—FGF2—prostate cancer	2.2e-05	4.52e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—ERBB2—prostate cancer	2.2e-05	4.52e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—KRAS—prostate cancer	2.2e-05	4.51e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—TP53—prostate cancer	2.2e-05	4.51e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—PIK3CA—prostate cancer	2.19e-05	4.5e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CG—prostate cancer	2.19e-05	4.5e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—STAT3—prostate cancer	2.18e-05	4.48e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TERT—prostate cancer	2.17e-05	4.46e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—NOS3—prostate cancer	2.17e-05	4.46e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CB—prostate cancer	2.17e-05	4.46e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—FGF2—prostate cancer	2.15e-05	4.41e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TP53—prostate cancer	2.12e-05	4.35e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NOS3—prostate cancer	2.12e-05	4.35e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—JAK2—prostate cancer	2.11e-05	4.33e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—AKT1—prostate cancer	2.1e-05	4.32e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—HIF1A—prostate cancer	2.08e-05	4.27e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—INS—prostate cancer	2.07e-05	4.26e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MDM2—prostate cancer	2.06e-05	4.23e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—JAK2—prostate cancer	2.06e-05	4.23e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CDKN1B—prostate cancer	2.04e-05	4.18e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CREBBP—prostate cancer	2.03e-05	4.17e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—ERBB2—prostate cancer	2.03e-05	4.17e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—LEP—prostate cancer	2.03e-05	4.17e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MYC—prostate cancer	2.03e-05	4.16e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—TGFB1—prostate cancer	2.02e-05	4.15e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—PIK3CA—prostate cancer	2.02e-05	4.14e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—IL6—prostate cancer	2.01e-05	4.13e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CAV1—prostate cancer	2.01e-05	4.13e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MDM2—prostate cancer	2.01e-05	4.13e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—IL6—prostate cancer	2.01e-05	4.13e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CB—prostate cancer	2e-05	4.12e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL2—prostate cancer	1.99e-05	4.09e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—KDR—prostate cancer	1.99e-05	4.08e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PTGS2—prostate cancer	1.99e-05	4.08e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—ERBB2—prostate cancer	1.98e-05	4.07e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—EGFR—prostate cancer	1.98e-05	4.07e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CB—prostate cancer	1.96e-05	4.02e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—IL6—prostate cancer	1.94e-05	3.99e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ESR1—prostate cancer	1.94e-05	3.98e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CD—prostate cancer	1.93e-05	3.95e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CTNNB1—prostate cancer	1.92e-05	3.95e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—BAD—prostate cancer	1.89e-05	3.88e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CDKN1B—prostate cancer	1.88e-05	3.86e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CDKN1A—prostate cancer	1.88e-05	3.86e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CXCL8—prostate cancer	1.88e-05	3.86e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PTEN—prostate cancer	1.88e-05	3.85e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—KRAS—prostate cancer	1.87e-05	3.84e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—AKT1—prostate cancer	1.86e-05	3.81e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—AKT1—prostate cancer	1.85e-05	3.81e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CDKN1B—prostate cancer	1.83e-05	3.77e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CG—prostate cancer	1.83e-05	3.76e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—APC—prostate cancer	1.83e-05	3.76e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—NOS3—prostate cancer	1.82e-05	3.73e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—AKT1—prostate cancer	1.82e-05	3.73e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EGF—prostate cancer	1.81e-05	3.72e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IRS1—prostate cancer	1.81e-05	3.72e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CASP3—prostate cancer	1.8e-05	3.69e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IL2—prostate cancer	1.8e-05	3.69e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—AKT1—prostate cancer	1.79e-05	3.68e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—EP300—prostate cancer	1.79e-05	3.67e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—IL6—prostate cancer	1.79e-05	3.67e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CTNNB1—prostate cancer	1.78e-05	3.65e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—GSK3B—prostate cancer	1.76e-05	3.61e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CCND1—prostate cancer	1.75e-05	3.59e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—SRC—prostate cancer	1.74e-05	3.57e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CDKN1A—prostate cancer	1.74e-05	3.56e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—INS—prostate cancer	1.73e-05	3.56e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CTNNB1—prostate cancer	1.73e-05	3.56e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PTEN—prostate cancer	1.73e-05	3.56e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PIK3CA—prostate cancer	1.72e-05	3.53e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MMP9—prostate cancer	1.7e-05	3.49e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CREBBP—prostate cancer	1.7e-05	3.49e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CDKN1A—prostate cancer	1.69e-05	3.48e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PTEN—prostate cancer	1.69e-05	3.47e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CB—prostate cancer	1.68e-05	3.45e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—STAT3—prostate cancer	1.68e-05	3.45e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IGF1—prostate cancer	1.68e-05	3.44e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—TP53—prostate cancer	1.66e-05	3.42e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PTGS2—prostate cancer	1.66e-05	3.42e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—EP300—prostate cancer	1.65e-05	3.39e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—AKT1—prostate cancer	1.65e-05	3.38e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MAP2K1—prostate cancer	1.62e-05	3.33e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—EP300—prostate cancer	1.61e-05	3.31e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CD—prostate cancer	1.61e-05	3.31e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—SRC—prostate cancer	1.61e-05	3.3e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SERPINE1—prostate cancer	1.59e-05	3.27e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—SRC—prostate cancer	1.57e-05	3.22e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—STAT3—prostate cancer	1.55e-05	3.18e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—FGF2—prostate cancer	1.54e-05	3.17e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—VEGFA—prostate cancer	1.53e-05	3.13e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—EGFR—prostate cancer	1.52e-05	3.13e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IL6—prostate cancer	1.52e-05	3.13e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NOS3—prostate cancer	1.52e-05	3.12e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—STAT3—prostate cancer	1.51e-05	3.1e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—JAK2—prostate cancer	1.48e-05	3.03e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PTEN—prostate cancer	1.45e-05	2.98e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MDM2—prostate cancer	1.44e-05	2.96e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—KRAS—prostate cancer	1.44e-05	2.96e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MYC—prostate cancer	1.44e-05	2.96e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—TGFB1—prostate cancer	1.44e-05	2.95e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ERBB2—prostate cancer	1.42e-05	2.92e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—EGFR—prostate cancer	1.41e-05	2.89e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—AKT1—prostate cancer	1.4e-05	2.88e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MYC—prostate cancer	1.4e-05	2.88e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CB—prostate cancer	1.4e-05	2.88e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TGFB1—prostate cancer	1.4e-05	2.88e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—EP300—prostate cancer	1.38e-05	2.84e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—EGFR—prostate cancer	1.37e-05	2.82e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CXCL8—prostate cancer	1.35e-05	2.77e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—KRAS—prostate cancer	1.33e-05	2.73e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CA—prostate cancer	1.32e-05	2.72e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CDKN1B—prostate cancer	1.32e-05	2.7e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—KRAS—prostate cancer	1.3e-05	2.66e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CASP3—prostate cancer	1.29e-05	2.65e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IL2—prostate cancer	1.29e-05	2.65e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CCND1—prostate cancer	1.26e-05	2.58e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CTNNB1—prostate cancer	1.24e-05	2.56e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CA—prostate cancer	1.22e-05	2.51e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MMP9—prostate cancer	1.22e-05	2.51e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CDKN1A—prostate cancer	1.22e-05	2.5e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PTEN—prostate cancer	1.21e-05	2.49e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CA—prostate cancer	1.19e-05	2.45e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL6—prostate cancer	1.17e-05	2.41e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EP300—prostate cancer	1.16e-05	2.38e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TP53—prostate cancer	1.15e-05	2.37e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SRC—prostate cancer	1.12e-05	2.31e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—VEGFA—prostate cancer	1.1e-05	2.25e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—STAT3—prostate cancer	1.08e-05	2.23e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—IL6—prostate cancer	1.08e-05	2.22e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—AKT1—prostate cancer	1.08e-05	2.22e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IL6—prostate cancer	1.06e-05	2.17e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CA—prostate cancer	1.02e-05	2.1e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MYC—prostate cancer	1.01e-05	2.07e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TGFB1—prostate cancer	1.01e-05	2.06e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—AKT1—prostate cancer	9.98e-06	2.05e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EGFR—prostate cancer	9.86e-06	2.02e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—AKT1—prostate cancer	9.74e-06	2e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—KRAS—prostate cancer	9.31e-06	1.91e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CA—prostate cancer	8.56e-06	1.76e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—AKT1—prostate cancer	8.36e-06	1.72e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TP53—prostate cancer	8.28e-06	1.7e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IL6—prostate cancer	7.58e-06	1.56e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—AKT1—prostate cancer	6.99e-06	1.44e-05	CbGpPWpGaD
